Rivo Bio describes new 5-HT2A receptor agonists

Aug. 7, 2025

Rivo Bio Inc. has disclosed compounds acting as 5-HT2A receptor agonists reported to be useful for the treatment of depression, schizophrenia and anxiety disorders.

Today's news in brief

BioWorld

BioWorld briefs for April 10, 2026.

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

News in brief

BioWorld Asia

BioWorld Asia briefs for April 7, 2026

Korsana boosts Alzheimer’s work with reverse merger, $380M financing

BioWorld Science

Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld

Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...